This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Actelion Pharmaceuticals Ltd. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Loïc Perchenet: Innovator in Pulmonary Arterial Hypertension Treatment
Introduction
Loïc Perchenet is a notable inventor based in Allschwil, Switzerland. He has made significant contributions to the field of medicine, particularly in the treatment of pulmonary arterial hypertension (PAH). His innovative approaches aim to improve patient outcomes and reduce disease progression.
Latest Patents
Loïc Perchenet holds a patent for "Methods of treating pulmonary arterial hypertension." This patent describes methods for reducing the risk of disease progression in patients with PAH. The approach involves administering an initial triple combination therapy that includes an endothelin receptor antagonist (ERA), a phosphodiesterase type 5 (PDE-5) inhibitor, and a prostacyclin receptor agonist (IP receptor agonist). This innovative treatment strategy represents a significant advancement in managing this challenging condition.
Career Highlights
Loïc Perchenet is associated with Actelion Pharmaceuticals Ltd., a company known for its focus on innovative treatments for pulmonary diseases. His work at Actelion has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research and development efforts.
Collaborations
Loïc has worked alongside Alessandro Maresta, enhancing the collaborative efforts within his team to drive forward innovative solutions in the treatment of PAH.
Conclusion
Loïc Perchenet's contributions to the field of pulmonary arterial hypertension treatment through his patent and work at Actelion Pharmaceuticals Ltd. highlight his commitment to improving patient care. His innovative methods represent a promising advancement in the management of this serious condition.